- Novartis held its 2q2011 earnings conference call on 7/19/2011 - click here for transcript link.
- NVS is partnered with Momenta Pharma $MNTA (see research page) for two complex generics - enoxaparin (branded is Lovenox from Sanofi $SNY) and glatiramer acetate (branded is Copaxone from Teva)
- These programs were not discussed in depth on this call, but sales figures given by NVS for generic lovenox can be used to calculate revenue sharing paid to Momenta. Note this product is now selling at a >$1 billion per year run rate.
- Quote: "So, in terms of Sandoz, the growth outlook, it's important to note that the enoxaparin launch boost annualizes from this quarter, from Q3 onward as we had launched in July of last year. As we said, we expect to deliver mid to high single-digit sales growth and that broadly covers the scenarios that we can foresee regarding enoxaparin competition. The growth in the second half of the year will slow due to a couple of factors; one is the animalization of enox as I mentioned"